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Obesity promotes chronic activation of mTORC1 and is a known risk factor for hepatic injury, inflammation,
and carcinogenesis. In this issue, Umemura et al. (2014) demonstrate that a persistent reduction in hepatic
mTORC1activity alsopromotes cell damageand inflammation andsensitizes the liver to cancer development.Perhaps too much of everything is
as bad as too little.—Edna Ferber
This quotation from the 20th century
American novelist applies to so many
facets of human life, that most would
consider the statement more aphoristic
than enlightening. From a health perspec-
tive, there is no better supportive example
of this axiom than the human diet, which,
in different parts of the world, aptly illus-
trates the devastating consequences of
undernutrition (too little) or excessive
food intake (too much). In developed
countries, too much caloric intake
coupled with too little physical activity
have fueled an epidemic of obesity that
threatens to overburden the healthcare
systemwith sundry, life-threateningmala-
dies. One of the many unfortunate
sequelae of the obesity epidemic is an
increasing incidence of hepatocellular
carcinoma (HCC), an aggressive disease
with limited treatment options (Caldwell
et al., 2004). Environmental factors, such
as persistent hepatitis B or C infection,
are etiologically linked to the majority of
cases of HCC; however, chronic overnu-
trition is a rapidly emerging etiologic fac-
tor for this disease (Sanyal et al., 2010).
Preclinical and clinical studies indicate
that the nutrient-stimulated, rapamycin-sensitive mammalian target of rapamycin
complex 1 (mTORC1) is both activated
and functionally important for HCC devel-
opment and progression (Bhat et al.,
2013). Strong evidence that HCC is char-
acterized by ‘‘too much’’ mTORC1 activ-
ity prompted clinical trials with rapamycin
analogs (rapalogs), which unfortunately
yielded disappointing results. An ironic
twist to this negative outcome is that the
clinical use of rapalogs to reduce
mTORC1 activity in HCC is associated
with increased liver injury, which could,
in principle, promote disease progression
(Yamanaka et al., 2013).
A article in this issue of Cell Metabolism
explores the impact of reduced hepatic
mTORC1 activity on diet- and carcin-
ogen-induced inflammation and HCC
development in mice (Umemura et al.,
2014). In the initial studies, mice were
fed a high-fat diet (HFD), and mTORC1
activity was systemically reduced by
treatment of the animals with rapamycin.
Consistent with expectations, rapamycin
treatmentmarkedly suppressed the accu-
mulation of free fatty acids in the livers
of these mice; however, chronic drug
treatment elicited additional alterations
in liver physiology that were consistent
with an enhanced inflammatory response
and hepatocellular damage. A noteworthyeffect of this drugwas a dramatic increase
in serum interleukin-6 (IL-6), the source of
which was presumably, but not defini-
tively, proven to be the liver. Rapamycin
is a well-established inducer of auto-
phagy, and Umemura et al. (2014) noted
that the livers of drug-treated mice dis-
played changes in autophagy biomarkers
indicative of increased autophagic flux in
liver cells. Interestingly, previous studies
showed that autophagy is required for
the production of IL-6 during oncogene-
induced stress (Narita et al., 2011). Future
studies should examine whether auto-
phagy supports IL-6 production and the
consequent activation of STAT3 in
the rapamycin-treated liver. Nonetheless,
the contributions of autophagy to HCC
development seem very complex, with
tumor promotion or suppression as out-
comes, depending on the evolutionary
stage of the HCC (Cui et al., 2013).
In subsequent studies, Umemura et al.
(2014) employed an elegant genetic
approach to examine whether the effects
of reduced mTORC1 activity on hepato-
cyte physiology were truly cell autono-
mous. The authors generated mice
bearing a hepatocyte-specific knockout
of the Raptor gene, which is specifically
associatedwith and required formTORC1
function. The RaptorDhep mice were
Figure 1. Roles of Aberrant mTORC1 Activity in the Etiology of Liver Disease and Liver
Cancer
Nutrient excess supports a persistent increase in mTORC1 activity, which, together with the abnormal
accumulation of free fatty acids, causes ER and oxidative stress, leading to liver injury, inflammation,
and HCC. Conversely, a chronic reduction in mTORC1 activity decreases hepatocyte fitness and stress
resistance and promotes a sustained increase in autophagy, together with the potentially linked produc-
tion of proinflammatory IL-6. These outcomes are exacerbated by a HFD, as is the progression from liver
injury to HCC.
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Previewshealthy at birth but, after a few months,
exhibited symptoms of liver dysfunc-
tion and damage, including hepatocyte
cell death. The RaptorDhep livers also
displayed clear signs of inflammation,
including the serum IL-6 elevation
originally observed by these authors in
rapamycin-treated wild-type mice. Liver-
specific loss of mTORC1 function also
enhanced the development of liver
fibrosis in mice fed a HFD. With this back-
drop of alterations in the liver, it is not
surprising that the RaptorDhep mice were
highly sensitized to hepatocellular dam-
age and carcinogenesis following com-
bined exposure to a HFD and the canoni-
cal liver carcinogen, diethylnitrosamine.
In summary, Umemura et al. (2014)
clearly demonstrated that deficient
mTORC1 function predisposes the liver
parenchyma to inflammation and hepato-
cellular damage, pathological changes
that are exacerbated by a HFD and
that set the stage for HCC develop-
ment (Figure 1). Remarkably, an earlier
study described similar outcomes after
imposing a directionally opposite alter-ation in mTORC1 activity in mice bearing
a liver-specific knockout of the Tsc1gene,
which encodes an essential component
of the mTORC1-inhibitory tuberous scle-
rosis complex in hepatocytes (Menon
et al., 2012). Apparently, the path to HCC
can be paved by alterations that result
in either chronically reduced or elevated
mTORC1 activity. Regardless of the
underlying etiology, liver carcinogenesis
represents the culmination of repeated,
futile cycles of liver cell damage and
death followed by proliferative regenera-
tion in an inflammatory microenviron-
ment. The regenerative process can be
mediated either by the proliferation and
differentiation of hepatic progenitor cells
(termed oval cells) or by the acquisition of
regenerative function by the hepatocytes
themselves (Menon et al., 2012; Mishra
et al., 2009). In the study by Menon et al.
(2012), the persistent increase inmTORC1
activity in Tsc1-deficient hepatocytes
results in cellular damage and death, due
in part to chronic endoplasmic reticulum
(ER) stress and suppression of cytoprotec-
tiveautophagy (Figure1). These responsesCell Metabopromote inflammation and the accumula-
tion of genetically damaged hepatocytes
that are driven to proliferate due to consti-
tutively active signaling through mTORC1.
Indeed, Menon et al. (2012) documented
that HCC development in the TSC1-defi-
cient livers is primarily a hepatocyte-driven
disease. In contrast, Umemura et al. (2014)
propose that persistent suppression of
mTORC1 activity in the liver leads to low-
level inflammation that is enhanced by
feeding a HFD. However, in this model,
hepatocytes bearing deficient mTORC1
activity are less competent to cope with
oxidative stress and other inflammation-
related insults, and the demise of these
hepatocytes further amplifies paren-
chymal inflammation and fibrosis. The
absence of mTORC1 might also impair
the ability of surviving hepatocytes to
undergo compensatory proliferation in
the model studied by Umemura et al.
(2014), suggesting that liver regeneration
and carcinogenesis in this setting are
attributable to the proliferation and even-
tual transformation of oval cells in the
promutagenic tissue milieu.
HCC is the fifth most common cancer
subtype worldwide, with a median sur-
vival of 6–16 months after diagnosis.
Health authorities are increasingly con-
cerned that the current epidemic of
obesity is fueling a significant increase in
the incidence of this deadly disease.
Persistent elevation of hepatic mTORC1
activity in the setting of overnutrition and
obesity, or conversely, protracted sup-
pression of mTORC1 activity induced by
rapamycin and related drugs, sets in
motion a spiraling sequence of pathologic
events that promotes HCC. It seems
that good liver health depends on just
the right amount of hepatic mTORC1
activity. Too little or too much mTORC1
signaling over the long term threatens
the integrity of this vital organ and, in
turn, the life of the host.REFERENCES
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Mitochondrial DNA diseases are relatively common, sometimes devastating, and transmitted exclusively
through the egg to children of carrier mothers. A study in Cell by Wang et al. (2014) adds the exciting possi-
bility of a new therapy for preventingmitochondrial disease transmission predicated on the use of polar body
genomes in mice.Mitochondria are energy generators,
present in thousands of copies per
cell, and inherited maternally. They con-
tain their own small genome in a cir-
cular chromosome that is uniquely
susceptible to pathologic mutations.
Diagnosis of mitochondrial DNA
(mtDNA) disease is often difficult given
the potential involvement of multiple tis-
sues, organs, or systems. In extreme
cases of homoplasmic mutations, when
all mtDNA is mutated, e.g., Leigh’s
Syndrome, catastrophic outcomes can
occur in affected children. The perva-
sive nature of the disease translates
into a paucity of specific clinical thera-
pies for the affected patient. However,
several approaches to prevent second-
generation transmission of mitochon-
drial DNA disease include pronuclear
and spindle transfer, both relying on
replacement of defective mitochondria
with nonpathogenic mtDNA from donor
zygotes or oocytes (Wallace and Chal-
kia, 2013).
Spindle transfer involves isolating and
transplanting meiotic metaphase chro-
mosomes from a mature oocyte into thecytoplasm of enucleated donor oocyte.
During pronuclear transfer, both male
and female pronuclei are removed from
the one-celled embryo or zygote and
transferred to the cytoplasm of donor
zygote. Efforts began in the United
Kingdom in 2005 with Human Fertiliza-
tion and Embryology Authority approval
of pronuclear transfer experimenta-
tion using clinically discarded zygotes.
Subsequently, pronuclear transfer was
reported with minimal (<2%) cotransfer
of mtDNA (Craven et al., 2010). An alter-
native approach involving the use of
spindle transfer has since been champ-
ioned because it involves manipulation
of oocytes, not zygotes, with efficacy
and safety demonstrated in monkeys by
live births, normal growth curves, and
maintained low levels of carryover mtDNA
from spindle donors (Lee et al., 2012;
Tachibana et al., 2009). Additionally,
spindle transfer in human oocytes from
donors with different mtDNA genotypes
supported fertilization, embryo develop-
ment, and stem cell isolation, all with
low mitochondrial carryover (Tachibana
et al., 2013).In a recent Cell paper, Wang et al.
(2014) directly compare pronuclear and
spindle transfer outcomes in mice and
demonstrate that the latter is associated
with a significant mtDNA carryover
(over 20%) in live offspring. The authors
further explored whether polar bodies
extruded during meiosis could be used
in the context of mtDNA replacement
(Figure 1A). Wang et al. reasoned that
the genetic material present in these
polar bodies could be recovered if these
structures were harvested in a timely
manner and transferred into enucleated
oocytes or zygotes. Their initial focus
was on the first polar body that was
used to replace a sister spindle in
metaphase II oocytes (Figure 1B). Polar
bodies were transferred into enucleated
oocytes from a mouse strain carrying
a different mtDNA haplotype allowing
quantitation of donor versus host
mtDNA. In an effort to double the yield
of reconstructed oocytes, the authors
carried out spindle and polar body trans-
fer from the same oocyte. Manipulated
oocytes were fertilized and mtDNA pres-
ence was subsequently quantitated in
